Business
Opthea Provides Corporate Update
Successful DFA settlement reached Company with cash and cash equivalents of approximately USD20M Dr Fred Guerard, CEO, Tom Reilly, CFO, and Sujal Shah, Director, to step down Dr Jeremy Levin to continue as Chairman and to assume additional responsibilities as of September 1st MELBOURNE, Australia and PRINCETON, N.J., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), today provided a corporate update following the successful settlement of the Development
About this update from Opthea Limited
[{"type":"image","alt":"Opthea Limited","displaySize":"","headline":null,"caption":"Opthea Limited","className":"","disableSlideshowImg":false,"size":{"original":{"width":182,"height":44,"url":"https://media.zenfs.com/en/globenewswire.com/c07427df91ee1cd5a8b901317d4291e5"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ULDvHcvRToYWZzZCS40V5g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTM2MDtoPTg3O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/c07427df91ee1cd5a8b901317d4291e5","width":182,"height":44}},"lazy":false},{"type":"text","content":"Successful DFA settlement reached","length":33,"tagName":"p"},{"type":"text","content":"Company with cash and cash equivalents of approximately USD20M ","length":62,"tagName":"p"},{"type":"text","content":"Dr Fred Guerard, CEO, Tom Reilly, CFO, and Sujal Shah, Director, to step down ","length":77,"tagName":"p"},{"type":"text","content":"Dr Jeremy Levin to continue as Chairman and to assume additional responsibilities as of September 1st","length":101,"tagName":"p"},{"type":"text","content":"MELBOURNE, Australia and PRINCETON, N.J., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), today provided a corporate update following the successful settlement of the Development Funding Agreement ("DFA") with the two investors under the DFA.","length":297,"tagName":"p"},{"type":"text","content":"DFA Settlement","length":14,"tagName":"p"},{"type":"text","content":"In March of 2025, after the primary endpoints were not met in both COAST and ShORe phase 3 clinical trials, Opthea, and Ocelot SPV LP and Sanba II Investment Company (together the "DFA Investors") agreed to discontinue the development of sozinibercept in wet AMD.","length":273,"tagName":"p"},{"type":"text","content":"As previously disclosed, certain termination events under the DFA could have triggered payments by the Company of up to USD680 million. In light of these matters, there was material uncertainty as to Opthea's ability to continue as a going concern and trading of Opthea’s stock on ASX and NASDAQ was suspended.","length":314,"tagName":"p"},{"type":"text","content":"After extensive negotiations, Opthea has reached a binding agreement with the DFA Investors to terminate the DFA. As part of the settlement arrangements, all parties have entered into an agreement of settlement and release ("Settl...